{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:53:39Z","timestamp":1788533619476,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"CBER"},{"DOI":"10.13039\/100000038","name":"FDA's Medical Countermeasures Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.yrtph.2019.104436","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T06:54:56Z","timestamp":1564728896000},"page":"104436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-6574","authenticated-orcid":false,"given":"Million A.","family":"Tegenge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Von Tungeln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mitkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Vanlandingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2019.104436_bib1","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.yrtph.2019.104436_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0264-410X(99)00263-7","article-title":"Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice","volume":"18","author":"Dupuis","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/cimm.1998.1283","article-title":"Dendritic cells internalize vaccine adjuvant after intramuscular injection","volume":"186","author":"Dupuis","year":"1998","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.yrtph.2019.104436_bib4","series-title":"Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Manufactured by ID Biomedical Corporation - Questions and Answers","author":"FDA","year":"2013"},{"key":"10.1016\/j.yrtph.2019.104436_bib5","series-title":"Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted Emulsion for Intramuscular Injection","author":"FDA","year":"2016"},{"key":"10.1016\/j.yrtph.2019.104436_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-1759(03)00081-4","article-title":"A simple and rapid vortex method for preparing antigen\/adjuvant emulsions for immunization","volume":"276","author":"Flies","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.yrtph.2019.104436_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2019.104436_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3382\/ps.0740666","article-title":"Vitamin E in viral inactivated vaccines","volume":"74","author":"Franchini","year":"1995","journal-title":"Poult. Sci."},{"key":"10.1016\/j.yrtph.2019.104436_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2019.104436_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/erv.11.170","article-title":"Aflunov(\u00ae): a prepandemic influenza vaccine","volume":"11","author":"Gasparini","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.yrtph.2019.104436_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0021-9150(94)90122-8","article-title":"Postabsorptive metabolism of dietary squalene","volume":"106","author":"Gylling","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yrtph.2019.104436_bib12","doi-asserted-by":"crossref","first-page":"15ra5","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2019.104436_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2019.104436_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2019.104436_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib16","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.02.012","article-title":"Beyond empiricism: informing vaccine development through innate immunity research","volume":"148","author":"Levitz","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.yrtph.2019.104436_bib17","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib18","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 Adjuvant: the Best Insurance against Influenza Strain Diversity","volume":"10","author":"O\u2019Hagan","year":"2011","journal-title":"Expert Rev Vaccinesm"},{"key":"10.1016\/j.yrtph.2019.104436_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","article-title":"MF59. Design and evaluation of a safe and potent adjuvant for human vaccines","volume":"6","author":"Ott","year":"1995","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.yrtph.2019.104436_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yrtph.2019.104436_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yrtph.2019.104436_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","article-title":"Transport of macromolecules across microvascular walls: the two-pore theory","volume":"74","author":"Rippe","year":"1994","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yrtph.2019.104436_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J. angiogenesis. Res."},{"key":"10.1016\/j.yrtph.2019.104436_bib25","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jat.3130","article-title":"Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines","volume":"35","author":"Segal","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.yrtph.2019.104436_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10928-013-9328-y","article-title":"A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines","volume":"40","author":"Tegenge","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.yrtph.2019.104436_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.yrtph.2015.02.005","article-title":"A first-generation physiologically based pharmacokinetic (PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant","volume":"71","author":"Tegenge","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104436_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yrtph.2016.08.003","article-title":"Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice","volume":"81","author":"Tegenge","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104436_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0264-410X(91)90155-Y","article-title":"Vitamin E adjuvant formulations in mice","volume":"9","author":"Tengerdy","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib30","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2019.104436_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0005-2760(82)90355-1","article-title":"Fate of intravenously administered squalene in the rat","volume":"712","author":"Tilvis","year":"1982","journal-title":"Biochim. Biophys. Acta Lipids Lipid Metab."},{"key":"10.1016\/j.yrtph.2019.104436_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02534687","article-title":"Dietary squalene increases tissue sterols and fecal bile acids in the rat","volume":"18","author":"Tilvis","year":"1983","journal-title":"Lipids"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019302004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019302004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:27:13Z","timestamp":1759494433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230019302004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"alternative-id":["S0273230019302004"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104436","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104436"}}